Pharmaceutical manufacturers are facing a new challenge. The recent patent cliff and the exponential growth in the development of high-value pharmaceutical products, biologically developed therapies and live vaccines in the last ten years, has resulted in a greater need for temperature-assured handling of drug product, from active ingredients to finished dosage form. This can be demonstrated by the fact that in 2013, seven of the top ten highest-selling pharma products were biologics, with global sales contribution from biologic drugs forecasted to jump from 23% in 2014 to 27% in 2020. Fiona Withey, Chief Executive Officer at PCI, shares her thoughts on cold chain outsourcing.

Comments are closed.

%d bloggers like this: